Colorectal CancerColorectal AdenocarcinomaColorectal Cancer Stage IIColorectal Cancer Stage IIIColorectal Cancer Recurrent
Investigational drug(s) / intervention(s)
CENSURE
CENSURE: A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
Study summary
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
* Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
* Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
* Confirmed cancer-free survivorship confirmed at the time of study inclusion.
Exclusion Criteria:
* Lack of written informed consent.
* Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
* Hereditary colorectal cancer syndromes (identified through genetic testing)
* Inflammatory bowel diseases
Primary outcome measure(s)
Recurrence-Free Survival — Up to 120 months Time from treatment completion to development of recurrence (or death)
Trial sites (4)
Facility
City
Region
Status
City of Hope Medical Center
Monrovia
California
Recruiting
Second Affiliated Hospital of Dalian Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.